CDC-RFA-GH-24-0069: Strengthening Capacity of Central Asia and Eastern Europe Countries to Implement Sustainable and Effective HIV/AIDS Prevention, Care, and Treatment and Health Security Programs under PEPFAR
Closed
This grant is closed. A newer notice from the same program is forecast: Capacity Building for National Immunization Programs in the Eastern Mediterranean Region (CDC-RFA-JG-27-0070). Status: Expected deadline February 12, 2027. It is in our archive of Centers for Disease Control - CGH notices from 2023.
Centers for Disease Control - CGH offered grants to any type of organization. It expected to make about 2 awards. Applications closed on March 4, 2024.
From the official notice on Grants.gov, last changed January 10, 2024. Checked November 7, 2026.
- Expected awards2
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | December 20, 2023 |
|---|---|
| Deadline | March 4, 2024 |
| Archived by Grants.gov | April 11, 2024 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Most of the money in the 2 programs behind this notice (60% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $3,200,000 for Year 1, subject to the availability of funds. This NOFO aims to enhance Central Asia's capacity to provide high-quality HIV/AIDS prevention, treatment, laboratory, and strategic information (SI) programs. The goal is to achieve epidemic control by 2030, following international standards (e.g., UNAIDS, International Health Regulations), and adapted to the local context. Based on PEPFAR's 5x3 Strategic Framework (September 2022), the focus is on leveraging investments to build resilient health systems that can effectively respond to public health threats. Key areas of focus include:Establishing access to evidence-based HIV prevention services such as case-finding, client-centric referral, pre-exposure prophylaxis (PrEP), and Medication-Assisted Therapy (MAT) services;Improving client-centric HIV treatment continuity to achieve 95-95-95 and address related co-morbidities through enhanced patient management, monitoring, laboratory capacity, care, treatment, and patient satisfaction;Strengthening capacity for collecting, managing, and utilizing SI to inform program implementation and impact assessment;Enhancing the health system’s ability to strengthen public health security, preparedness, and response;Ensuring sustained, resilient public health programs at individual, facility, and organizational levels to achieve HIV/AIDS epidemic control; andCoordinating with key community and relevant stakeholders for evidence-based policy development, sustained program design, financing, and implementation.
Who has won Global AIDS grants before
From fiscal 2021 to 2025, Global AIDS (93.067) awarded $7.6 billion across 521 grant awards, an average of $14.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 32 | $684 million |
| Elizabeth Glaser Pediatric AIDS Foundation | District of Columbia | 13 | $387 million |
| Management and Development for Health | 5 | $282 million | |
| Apin Public Health Initiatives LTD/Gte | 4 | $209 million | |
| University of Washington | Washington | 8 | $195 million |
Who has won Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security grants before
From fiscal 2021 to 2025, Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security (93.318) awarded $1.3 billion across 306 grant awards, an average of $4.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| African Field Epidemiology Network LTD | 6 | $147 million | |
| The Task Force for Global Health, Inc. | Georgia | 7 | $138 million |
| World Health Organization, Somalia | 14 | $125 million | |
| Association of Public Health Laboratories, Inc. (the) | Maryland | 3 | $61.5 million |
| The Johns Hopkins University | Maryland | 5 | $42.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-JG-27-0070, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-GH-24-0069 still open?
No. It closed on March 4, 2024. A newer notice is forecast: CDC-RFA-JG-27-0070, expected deadline February 12, 2027.
Who can apply for Strengthening Capacity of Central Asia and Eastern Europe Countries to Implement Sustainable and Effective HIV/AIDS Prevention, Care, and Treatment and Health Security Programs under PEPFAR?
Centers for Disease Control - CGH accepted applications from any type of organization.
What is the deadline for Strengthening Capacity of Central Asia and Eastern Europe Countries to Implement Sustainable and Effective HIV/AIDS Prevention, Care, and Treatment and Health Security Programs under PEPFAR?
Closed March 4, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has won Global AIDS grants before?
The largest recipients over five fiscal years were The Trustees of Columbia University in the City of New York, Elizabeth Glaser Pediatric AIDS Foundation, Management and Development for Health. The program made 521 awards worth $7.6 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)